{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:00:41Z","timestamp":1791234041065,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ctrv.2025.103064","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:29:27Z","timestamp":1765326567000},"page":"103064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-4486","authenticated-orcid":false,"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Bruschieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Riboldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Vavassori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Seghezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina De","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2025.103064_b0005","doi-asserted-by":"crossref","unstructured":"Oka R, Utsumi T, Noro T, et al. Progress in oligometastatic prostate cancer: emerging imaging innovations and therapeutic approaches. Cancers (Basel). 2024;16(3):507. Published 2024 Jan 24. doi:10.3390\/cancers16030507.","DOI":"10.3390\/cancers16030507"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103064_b0010","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41391-023-00688-w","article-title":"The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: a review","volume":"26","author":"Vanden Berg","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103064_b0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semradonc.2025.04.011","article-title":"Debate 3: oligometastatic hormone sensitive prostate cancer management: systemic therapy approach","volume":"35","author":"von Amsberg","year":"2025","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ctrv.2025.103064_b0020","doi-asserted-by":"crossref","unstructured":"Abdel-Aty H, Hujairi N, Murray I, Yogeswaran Y, van As N, James N. The quantitative impact of prostate-specific membrane antigen (PSMA) PET\/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implications. BJR Open. 2024;6(1):tzae040. Published 2024 Nov 8. doi:10.1093\/bjro\/tzae040.","DOI":"10.1093\/bjro\/tzae040"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103064_b0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOU.0000000000001251","article-title":"Prostatectomy and other local treatments for oligometastatic prostate cancer: recent and ongoing trials","volume":"35","author":"Fang","year":"2025","journal-title":"Curr Opin Urol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103064_b0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.4103\/iju.iju_60_23","article-title":"Oligometastatic carcinoma prostate - an overview of the last decade","volume":"39","author":"Shah","year":"2023","journal-title":"Indian J Urol"},{"key":"10.1016\/j.ctrv.2025.103064_b0035","article-title":"Metastasis-directed therapy in oligometastatic prostate cancer: biological rationale and systematic review of published data","volume":"17(8):1256","author":"Fiorica","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2025.103064_b0040","doi-asserted-by":"crossref","unstructured":"Cheng B, He H, Chen B, et al. Assessment of treatment outcomes: cytoreductive surgery compared to radiotherapy in oligometastatic prostate cancer - an in-depth quantitative evaluation and retrospective cohort analysis. Int J Surg. 2024;110(6):3190-3202. Published 2024 Jun 1. doi:10.1097\/JS9.0000000000001308.","DOI":"10.1097\/JS9.0000000000001308"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103064_b0045","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/iju.15540","article-title":"Local treatment benefits patients with oligometastatic prostate cancer: a systematic review and meta-analysis","volume":"31","author":"Sun","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctrv.2025.103064_b0050","doi-asserted-by":"crossref","unstructured":"Xue P, Wu Z, Wang K, Gao G, Zhuang M, Yan M. Oncological outcome of combining cytoreductive prostatectomy and metastasis-directed radiotherapy in patients with prostate cancer and bone oligometastases: a retrospective cohort study. Cancer Manag Res 2020;12:8867-8873. Published 2020 Sep 23. doi:10.2147\/CMAR.S270882.","DOI":"10.2147\/CMAR.S270882"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103064_b0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12254-023-00934-w","article-title":"Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review","volume":"17","author":"Br\u00f6nimann","year":"2024","journal-title":"Memo"},{"key":"10.1016\/j.ctrv.2025.103064_b0060","doi-asserted-by":"crossref","unstructured":"Ying W, Ding Z, He Y, et al. Surgery, radiotherapy and endocrine therapy for oligometastatic prostate cancer efficacy: a systematic review and network meta-analysis. PeerJ. 2025;13:e19819. Published 2025 Aug 29. doi:10.7717\/peerj.19819.","DOI":"10.7717\/peerj.19819"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103064_b0065","article-title":"Efficacy and safety of metastatic directed treatment of oligometastatic disease: results of a meta-analysis","volume":"10","author":"Berner-Wygoda","year":"2025","journal-title":"Adv Radiat Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103064_b0070","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00345-022-04239-1","article-title":"What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?","volume":"41","author":"Baboudjian","year":"2023","journal-title":"World J Urol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103064_b0075","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.21037\/tau-20-1033","article-title":"Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review","volume":"10","author":"Mahjoub","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ctrv.2025.103064_b0080","article-title":"Molecular mechanisms related with oligometastatic prostate cancer-is it just a matter of numbers?","volume":"14(3):766","author":"Surcel","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103064_b0085","doi-asserted-by":"crossref","first-page":"648","DOI":"10.21037\/apm.2020.04.21","article-title":"Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?\u2014evidence from a meta-analysis","volume":"9","author":"Xiao","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103064_b0090","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1080\/0284186X.2022.2132113","article-title":"The current role of local treatment in metastatic prostate cancer: systematic review and meta-analysis","volume":"61","author":"Baccaglini","year":"2022","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103064_b0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctrv.2025.103064_b0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13014-024-02559-7","article-title":"Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Persson","year":"2024","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103064_b0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"issue":"1107","key":"10.1016\/j.ctrv.2025.103064_b0110","article-title":"Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence","volume":"93","author":"Yan","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ctrv.2025.103064_b0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12957-022-02715-x","article-title":"Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis","volume":"20","author":"Mao","year":"2022","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ctrv.2025.103064_b0120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12957-021-02265-8","article-title":"The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis","volume":"19","author":"Cheng","year":"2021","journal-title":"World J Surg Oncol"},{"issue":"38","key":"10.1016\/j.ctrv.2025.103064_b0125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030671","article-title":"Cytoreductive radical prostatectomy or radiation therapy for metastatic prostate cancer: evidence from meta-analysis","volume":"101","author":"Peng","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103064_b0130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4111\/icu.20230058","article-title":"Cytoreductive prostatectomy may improve oncological outcomes in oligometastatic prostate cancer: an updated meta-analysis","volume":"64","author":"Chung","year":"2023","journal-title":"Investig Clin Urol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103064_b0135","first-page":"655","article-title":"Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: a meta-analysis","volume":"18","author":"Shemshaki","year":"2021","journal-title":"Urol J"},{"key":"10.1016\/j.ctrv.2025.103064_b0140","article-title":"Role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis","volume":"38(1)","author":"Wang","year":"2018","journal-title":"Biosci Rep"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103064_b0145","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000508415","article-title":"Impact of radiotherapy on prognosis in patients diagnosed with metastatic prostate cancer: a systematic review and meta-analysis","volume":"105","author":"Liu","year":"2021","journal-title":"Urol Int"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103064_b0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/COC.0000000000000635","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer recurrence: a meta-analysis","volume":"43","author":"Viani","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103064_b0155","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euo.2024.03.007","article-title":"Impact of local therapies on local event suppression in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Tsuboi","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103064_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304963","article-title":"Prognostic significance of additional localized treatment to the primary lesion in patients undergoing hormone therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"19","author":"Yamada","year":"2024","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103064_b0165","first-page":"1082","article-title":"Does surgery benefit patients with oligometastatic or metastatic prostate cancer? A systematic review and meta-analysis","volume":"81","author":"Si","year":"2021","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103064_b0170","first-page":"451","article-title":"Impact of radiotherapy on progression and failure-free survival in metastatic prostate cancer: systematic review and meta-analysis","volume":"30","author":"Lumen","year":"2023","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103064_b0175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Ablative stereotactic radiotherapy for oligometastatic cancer: systematic review and meta-analysis of prospective trials","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103064_b0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/14737140.2025.2509760","article-title":"Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer","volume":"25","author":"Ingrosso","year":"2025","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:02:41Z","timestamp":1767168161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":36,"alternative-id":["S0305737225001860"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103064","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary tumor and metastasis-directed treatment for oligometastatic prostate cancer: An umbrella review of meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103064"}}